Find a Product

Foretinib (GSK1363089)

Foretinib (GSK1363089) is a synthetic small anticancer molecule developed by GlaxoSmithKline after synthesis by Exelixis. Potently and ATP-competitively inhibits MET and VEGFR2 (IC50=0.4 and 0.9nM, respectively), kinase enzymes believed to promote tumor growth and angiogenesis. Currently in phase 1b/2 clinical trials for breast cancer and NSCLC.

Catalog No. Size Price Quantity
92-1238 5 mg $322.00

For account specific pricing, please contact Customer Service at customerservicedrx@eurofins.com.
Description
Foretinib (GSK1363089)
Compound Type
Agonist
Storage
-20°C
Source
Synthetic
Cells were plated in a 384-well plate and incubated overnight at 37°C/5% CO₂ to allow the cells to attach and grow. Cells were then stimulated with a control compound, using the assay conditions described below. Following treatment, signal was detected using the InCELL Hunter Detection Kit according to the recommended protocol.